Grace Therapeutics, Inc.
GRCE
NASDAQ·Healthcare·Biotechnology·Mkt cap $34.2M
$2.10
▼ -1.87%
P/E
-1.53
Mkt Cap
$34.2M
52-Wk Range
$1.79–$5.18
52-Week Range
$1.79 - $5.18
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 35.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Orphan drug designation enabling accelerated regulatory pathways and market exclusivity
- Focused pipeline targeting rare diseases with limited treatment alternatives
- Novel drug delivery mechanisms (intravenous infusion, oral spray, topical film)
- Canadian regulatory expertise with North American expansion potential
Bear Case
1 risk
- Low volatility (beta 0.4).
Growth
Stable outlook
Clinical trial progression and regulatory approvals for GTX-104, GTX-102, and GTX-101
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Weak
-8.7% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying GRCE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 13, 2026
Reported EPS of -$0.91 vs -$0.13 consensus (-603.8% surprise).
EPS surprise · last 4Q
1 of 2 beats
Estimate
Actual
Q3 26
-603.8%
Q2 26
+70.8%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q1 24
Q2 24
Q3 24
Q4 25
Q1 25
Q2 25
Q3 25
Q1 27
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Craig-Hallum · $4.00 · Apr 24, 2026
vs Industry
How GRCE stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related